Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk

Jang, Ji-Hyun; Cotterchio, Michelle; Borgida, Ayelet; Gallinger, Steven; Cleary, Sean P.

doi:10.1093/carcin/bgs028

Cited by 37 publications

(24 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To date, at least six case-control studies have addressed this association (Bartsch et al, 1998;Liu et al, 2000;Duell et al, 2002;Jiao et al, 2007;Vrana et al, 2009;Jang et al, 2012). All the studies were conducted in Western countries, with the exception of a population-based case-control study in the San Francisco Bay area, in which a small number of Asian participants were included (Duell et al, 2002).…”

Section: Discussionmentioning

confidence: 99%

“…All the studies were conducted in Western countries, with the exception of a population-based case-control study in the San Francisco Bay area, in which a small number of Asian participants were included (Duell et al, 2002). No main effects of the GSTT1 and GSTM1-null genotypes on pancreatic cancer risk were noted in any of the studies, with the exception of a population-based case-control study conducted in Canada (Jang et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…For GSTP1, a single nucleotide substitution (A"G) at position 313 of the GSTP1 gene (rs1695) substantially diminishes GSTP1 enzyme activity (Moyer et al, 2006). Loss-offunction (LoF) deletion polymorphisms in the GSTM1 and GSTT1 genes have been linked to an increased risk for many cancers, including head and neck, lung, liver, colon and pancreatic cancers (Geisler et al, 2001;Moore et al, 2005;White et al, 2008;Carlsten et al, 2008;Cote et al, 2009;Jang et al, 2012). Compared with GSTT1 and GSTM1 genetic polymorphisms (Bartsch et al,1998;Liu et al, 2000;Duell et al, 2002;Jiao et al, 2007;Vrana et al, 2009;Jang et al, 2012), very few studies have studied GSTP1 genetic polymorphisms and their associations with pancreatic cancer risk.…”

Section: Introductionmentioning

confidence: 99%

“…Loss-offunction (LoF) deletion polymorphisms in the GSTM1 and GSTT1 genes have been linked to an increased risk for many cancers, including head and neck, lung, liver, colon and pancreatic cancers (Geisler et al, 2001;Moore et al, 2005;White et al, 2008;Carlsten et al, 2008;Cote et al, 2009;Jang et al, 2012). Compared with GSTT1 and GSTM1 genetic polymorphisms (Bartsch et al,1998;Liu et al, 2000;Duell et al, 2002;Jiao et al, 2007;Vrana et al, 2009;Jang et al, 2012), very few studies have studied GSTP1 genetic polymorphisms and their associations with pancreatic cancer risk. Only one previous study reported that GSTP1 polymorphisms were significantly associated with pancreatic cancer survival (Jiao et al, 2007) Because the frequencies of GST genotypes vary across populations and ethnicities (Di Pietro et al, 2010), large inter-individual differences might exist in the metabolic response to carcinogen exposure.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Lack of Associations between Genetic Polymorphisms in GSTM1, GSTT1 and GSTP1 and Pancreatic Cancer Risk: A Multi-Institutional Case-Control Study in Japan

Yamada

Ozaka²,

Inoue³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: We aimed to evaluate the role of genetic polymorphisms in tobacco carcinogen-metabolizing genes and their interactions with smoking in a hospital-based case-control study of Japanese subjects. Materials and Methods: We examine the associations of pancreatic cancer risk with genetic polymorphisms in GSTM1, GSTT1 and GSTP1, phase II enzymes that catalyze the conjugation of toxic and carcinogenic electrophilic molecules. The study population consisted of 360 patients and 400 control subjects, who were recruited from several medical facilities in Japan. Unconditional logistic regression methods were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between genotypes and pancreatic cancer risk. Results: Among the control subjects, the prevalence of the GSTM1-null genotype and the GSTT1-null genotype was approximately 56% and 48%, respectively. Cases and controls were comparable in terms of GSTM1 and GSTT1 genotype distributions. Neither of the deleted polymorphisms in GSTM1 and GSTT1 was associated with the risk of pancreatic cancer, with an age-and sex-adjusted OR of 0.99 (95%CI: 0.74-1.32) for the GSTM1-null genotype, and 0.98 (95%CI: 0.73-1.31) for the GSTT1-null genotype. The OR was 0.97 (95%CI: 0.64-1.47) for individuals with the GSTM1 and GSTT1-null genotypes compared with those with the GSTM1 and GSTT1-present genotypes. No synergistic effects of smoking or GST genotypes were observed. Conclusions: Our results indicate no overall association between the GSTM1 and GSTT1 deletion polymorphisms and pancreatic cancer risk in the Japanese subjects in our study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lack of Associations between Genetic Polymorphisms in GSTM1, GSTT1 and GSTP1 and Pancreatic Cancer Risk: A Multi-Institutional Case-Control Study in Japan

Yamada

Ozaka²,

Inoue³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Tobacco smoking releases many carcinogens. A recent study examined several detoxifying genes in 455 patients with pancreatic cancer [20]. Variants in genes such as CYP1B1-4390-GG and uridine 5′-diphosphoglucuronosyltransferase reduced the risk of pancreatic cancer, whereas variants in others, such as GSTM1, increased risk.…”

Section: Smokingmentioning

confidence: 99%

Epidemiology of Pancreatic and Periampullary Cancer

Thapa

2015

Indian J Surg

View full text Add to dashboard Cite

Pancreatic cancer is an important public health problem, although infrequent but with an exceptionally high mortality rate worldwide. Given that the majority of cancers occur in association with smoking, diabetes, pancreatitis, genetic factors, and others and with a growing population worldwide in mind, more cases would be expected in the near future giving further impetus to investigating prevention and treatment strategies to this international issue. The representative data on epidemiology of carcinoma of pancreas in India and Nepal are very poor. While there are many questions to be resolved, it is apparent that many facets of pancreatic cancer are becoming increasingly understood, and prospects for prevention are becoming apparent. Hence, screening research, recommendations, and implementation is an obvious priority. Although previous studies have contributed to the knowledge of carcinoma of pancreas epidemiology, such association needs to be further verified with proper epidemiological work. A new and global approach to the study of carcinoma of pancreas epidemiology is required if the disease prevention and treatment strategies are to be adequately directed and supported in the coming years. The collection and analysis of epidemiologic carcinoma of pancreas data will play a critical role in guiding future disease prevention strategies and optimizing patient management.

show abstract

The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants

Laish,

Schechter,

Dancour

et al. 2023

Cancer

View full text Add to dashboard Cite

BackgroundSurveillance of high‐risk individuals for pancreatic ductal adenocarcinoma (PDAC) is recommended. This study aimed to determine the prevalence and outcomes of PDAC and its precursor lesions in BRCA1/2 pathogenic variants (PVs) carriers undergoing pancreatic surveillance.MethodsA retrospective multicenter cohort study of pancreatic surveillance outcomes in Israeli BRCA1/2 carriers preferably with a family history of PDAC.ResultsA total of 180 asymptomatic carriers participated in the screening programs, including 57 (31.7%) with BRCA1 PVs, 121 (67.2%) with BRCA2 PVs, and 12 (6.6%) with PVs in BRCA1/2 and other genes, for a median follow‐up period of 4 years. Ninety‐one individuals (50.5%) fulfilled the International Cancer of the Pancreas Screening (CAPS) criteria for surveillance whereas 116 (64.4%) fulfilled the American College of Gastroenterology (ACG) criteria. There were four cases of adenocarcinoma and four cases of grade 1‐neuroendocrine tumor (G1‐NET). All were BRCA2 carriers, and two had no family history of PDAC. Three cancer patients were at resectable stages (IA, IIA, IIB) whereas one had a stage IIIB tumor. Of the G1‐NET cases, one had surgery and the others were only followed. Success rate for detection of confined pancreatic carcinoma was thus 1.6% (three of 180) in the whole cohort, 1.6% (two of 116) among individuals who fulfilled ACG criteria and 2.2% (two of 91) in those fulfilling CAPS criteria for surveillance.ConclusionsDespite the low detection rate of PDAC and its' high‐risk neoplastic precursor lesions among BRCA1/2 carriers undergoing pancreatic surveillance, 75% of cancer cases were detected at a resectable stage.

show abstract

Genetic variants in carcinogen-metabolizing enzymes, cigarette smoking and pancreatic cancer risk

Cited by 37 publications

References 51 publications

Lack of Associations between Genetic Polymorphisms in GSTM1, GSTT1 and GSTP1 and Pancreatic Cancer Risk: A Multi-Institutional Case-Control Study in Japan

Lack of Associations between Genetic Polymorphisms in GSTM1, GSTT1 and GSTP1 and Pancreatic Cancer Risk: A Multi-Institutional Case-Control Study in Japan

Epidemiology of Pancreatic and Periampullary Cancer

The benefit of pancreatic cancer surveillance in carriers of germline BRCA1/2 pathogenic variants

Contact Info

Product

Resources

About